熱門資訊> 正文
Kodiak Sciences强调1b阶段结果，KSI-101可快速干燥视网膜并具有临床意义的视力改善
2025-09-15 19:13
- Kodiak Sciences Inc.(KOD) 0
- Kadem Sustainable Impact Corp Ordinary Shares - Class A(KSI) 0
- HEALTHPEAK PROPERTIES INC(PEAK) 0
- Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain)
- A single dose of KSI-101 resulted in the majority of patients achieving resolution of intra-retinal and sub-retinal fluid and over 90% of patients achieved retinal dryness by Week 8
- The Phase 3 PEAK and PINNACLE studies of KSI-101 are actively enrolling, testing the top two dose levels (5 mg and 10 mg) in patients with MESI
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
